William Blair Analysts Decrease Earnings Estimates for TLX

Telix Pharmaceuticals Limited (NASDAQ:TLX - Free Report) - Stock analysts at William Blair decreased their FY2025 earnings estimates for Telix Pharmaceuticals in a research report issued to clients and investors on Monday, July 14th. William Blair analyst A. Hsieh now anticipates that the company will earn $0.49 per share for the year, down from their prior estimate of $0.83. William Blair currently has a "Outperform" rating on the stock. The consensus estimate for Telix Pharmaceuticals' current full-year earnings is $0.24 per share. William Blair also issued estimates for Telix Pharmaceuticals' FY2026 earnings at $0.65 EPS and FY2027 earnings at $0.88 EPS.

TLX has been the subject of a number of other reports. Wedbush reaffirmed an "outperform" rating and set a $22.00 price target on shares of Telix Pharmaceuticals in a report on Thursday, June 12th. HC Wainwright initiated coverage on Telix Pharmaceuticals in a report on Thursday, July 3rd. They issued a "buy" rating and a $23.00 price target for the company.

Telix Pharmaceuticals Stock Performance

Shares of NASDAQ TLX traded up $0.44 during midday trading on Wednesday, reaching $16.11. 21,457 shares of the company traded hands, compared to its average volume of 28,972. Telix Pharmaceuticals has a 12 month low of $13.61 and a 12 month high of $30.36. The company has a quick ratio of 2.66, a current ratio of 2.78 and a debt-to-equity ratio of 0.99. The stock's 50-day simple moving average is $16.52 and its 200-day simple moving average is $16.95.

Institutional Investors Weigh In On Telix Pharmaceuticals

A hedge fund recently bought a new stake in Telix Pharmaceuticals stock. Private Advisor Group LLC acquired a new position in Telix Pharmaceuticals Limited (NASDAQ:TLX - Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 10,140 shares of the company's stock, valued at approximately $170,000.

About Telix Pharmaceuticals

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.